JBF Capital’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

JBF Capital’s Portfolio ARLZ Stock Details ARLZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,076	Closed	-$1K	–	124
2017 Q2	$1K	Hold	1,076	–	–	﹤0.01%	119
2017 Q1	$2K	Buy	+1,076	New	+$4.04K	﹤0.01%	118
2016 Q3	–	Sell	-1,076	Closed	-$4K	–	136
2016 Q2	$4K	Hold	1,076	–	–	﹤0.01%	126
2016 Q1	$4K	Buy	+1,076	New	+$5.55K	﹤0.01%	137

Other funds holding ARLZ

PCM

PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CIM

Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return

BAS

Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return

JBF Capital's ARLZ Position: Q3 2017 in Review

JBF Capital sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2017, closing a stake of 1,076 shares — an estimated $1K sold.

JBF Capital first reported a position in ARLZ in Q1 2016 and held it in 4 quarters. The position peaked at $4K in Q2 2016. 59 funds tracked by Wall St. Rank hold ARLZ as of Q3 2017.

JBF Capital reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2017 after selling out during the quarter.
JBF Capital sold 1,076 Aralez Pharmaceuticals Inc. shares in Q3 2017, an estimated $1K.
JBF Capital first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 4 quarters.
JBF Capital's Aralez Pharmaceuticals Inc. position peaked at $4K in Q2 2016.
59 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2017.

Based on JBF Capital's 13F filing for Q3 2017, filed 13 Nov 2017.